MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31

DataMeds AI, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026

$2.67+0.04 (+1.52%)

Close on Oct 19, 2026

Market cap: $6.87M
P/E (TTM): –
Dividend yield: –

SEC filings

40 of DataMeds AI's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Oct 19, 2026	Oct 20, 2026	SEC EDGAR
Current report	8-K	Oct 13, 2026	Oct 16, 2026	SEC EDGAR
Current report	8-K	Oct 13, 2026	Oct 13, 2026	SEC EDGAR
Current report	8-K	Sep 11, 2026	Sep 17, 2026	SEC EDGAR
Current report	8-K	Sep 11, 2026	Sep 16, 2026	SEC EDGAR
Current report	8-K	Aug 17, 2026	Aug 18, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 17, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	Jul 27, 2026	Jul 29, 2026	SEC EDGAR
Current report	8-K	Jul 20, 2026	Jul 21, 2026	SEC EDGAR
Current report	8-K	Jun 9, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 29, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 21, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 21, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 19, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 19, 2026	SEC EDGAR
Current report	8-K	May 15, 2026	May 19, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 18, 2026	SEC EDGAR
Current report	8-K	May 1, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 4, 2026	May 4, 2026	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2025	Apr 24, 2026	SEC EDGAR
Current report	8-K	Apr 17, 2026	Apr 17, 2026	SEC EDGAR
Current report	8-K	Apr 3, 2026	Apr 9, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 7, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 20, 2026	SEC EDGAR
Current report	8-K	Mar 6, 2026	Mar 11, 2026	SEC EDGAR
Current report	8-K	Mar 9, 2026	Mar 9, 2026	SEC EDGAR
Current report	8-K	Feb 4, 2026	Feb 13, 2026	SEC EDGAR
Current report	8-K	Feb 4, 2026	Feb 9, 2026	SEC EDGAR
Current report	8-K	Feb 1, 2026	Feb 5, 2026	SEC EDGAR
Current report	8-K	Jan 16, 2026	Jan 20, 2026	SEC EDGAR
Current report	8-K	Jan 5, 2026	Jan 8, 2026	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 19, 2025	SEC EDGAR
Current report	8-K	Dec 10, 2025	Dec 16, 2025	SEC EDGAR
Current report	8-K	Dec 8, 2025	Dec 8, 2025	SEC EDGAR
Current report	8-K	Dec 4, 2025	Dec 5, 2025	SEC EDGAR
Current report	8-K	Nov 26, 2025	Nov 26, 2025	SEC EDGAR
Current report	8-K	Nov 24, 2025	Nov 25, 2025	SEC EDGAR
Current report	8-K	Nov 20, 2025	Nov 20, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in DataMeds AI's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-50 reverse split on Aug 17, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MEDS.

Revenue growth-78.2% · median -48.1%

Gross margin-90.6% · median 34.8%

Operating margin-875.7% · median -100.8%

Net margin-1100.3% · median -419.8%

Company	Revenue	Growth
COSM	$73.73M	+33.8%
MEDS	$8.02M	-78.2%
STEK	$2.40M	-38.6%
NASC	$1.03M	-57.7%
ESYN	$389.74K	-68.5%
HKPD	–	–

Company

Next earnings (est.): Nov 19, 2026, after close
Exchange: Nasdaq
Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Fiscal year ends: December 31
Employees: 35
Held by institutions: 1.7%
Auditor: Suri & Co., Chartered Accountants
SEC CIK: 2030763

Advertisement
300 × 250